Blood Journals Portfolio/LinkedIn
Sep 8, 2025, 03:48
Blood Podcast Alert: Voxelotor Drops, Pediatric SCD, Thrombosis in VEXAS Syndrome and TKIs in ALL
Blood Journals Portfolio shared on LinkedIn:
”September is Sickle Cell Disease Awareness Month and together we are working to conquer SCD!
Effects of voxelotor on cerebral blood flow in pediatric sickle cell disease; thrombosis in Vexas syndrome; response to tyrosine kinase inhibitors in ABL-class acute lymphoblastic leukemia describes how voxelotor is raising hemoglobin.
Highlights are:
- Kids + sickle cell + voxelotor: Imagine your kid’s brain saying “thanks” while your hemoglobin goes up, up, up. Voxelotor drops cerebral blood flow and oxygen extraction to more normal levels—like a spa retreat for tiny brains in crisis.
- VEXAS syndrome, meet your match: Thrombosis stages its dramatic entrance—because immune dashboards love throwing plot twists.
- ABL-class ALL hitting back: Tyrosine kinase inhibitors show they still remember their moves—clocking responses like a perfect encore.
Listen to the full episode here.”
Stay tuned for the podcast series in hematology with Hemostasis Today.
-
Jan 31, 2026, 16:35IV Thrombolysis Does Not Improve Vision in Acute CRAO: Ahmed Koriesh on TenCRAOS Study
-
Jan 31, 2026, 16:24Joyce John Chalakkal: The Dangerous Area of The Face….
-
Jan 31, 2026, 16:04Rayya Saadiq Reflects On Qatar Health Congress 2026
-
Jan 31, 2026, 15:12Amar Raval on Oral Thin Film Drug Delivery Systems for Thrombosis Therapy
-
Jan 31, 2026, 14:40Heghine Khachatryan on WFH’s Call to Advance Health Equity for People with Bleeding Disorders
-
Jan 31, 2026, 14:10Emilia Arturo: Snake Venom, Clotting, and CryoEM!
-
Jan 31, 2026, 08:13Ming Y Lim On The Value of National Mentorship
-
Jan 31, 2026, 06:37Christian Schulze Presents The Post-Hoc Analysis of the DanGer Shock Trial
-
Jan 31, 2026, 06:27Negative Trials Matter: Anne Hege Aamodt Shares The TenCRAOS Trial